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world expert in animal models of inflam-
mation having made many contributions to 
interleukin-1 (IL-1) and TNF. For example, 
Ghezzi was the first to report that hypoxia 
induced IL-1β and TNFα.
In addition to their own chapters, the 
invited contributions are easy to read and 
each addresses a different aspect of this 
growing field of investigation. Driving the 
field are the clinical trials of EPO in patients 
with cerebral vascular accidents (stroke) 
and acute myocardial infarction, in which 
a benefit was reported. New clinical trials are 
presently underway. Experimental autoim-
mune encephalomyelitis (EAE) is the well 
established model for the human disease 
Multiple Sclerosis. The therapeutic ben-
efit of EPO in this model is well-described 
in a chapter by Cerevellini, Ghezzi, and 
Mengozzi. It seems that this disease as well 
as ALS are ideally suited for EPO testing.
The chapters provide clear information 
for both the novice entering the field or 
the investigator who studies mechanisms 
of cell death. Needless to write, the book is 
highly useful to the field of neurodegenera-
tion. The first chapter by Brines and Cerami 
on the structure-function relationships of 
the unique, alternate EPO receptor is well 
written with clear diagrams showing the 
domains of the heterodimeric EPO receptor 
that triggers the protective pathway. Other 
chapters include explanations on EPO and 
non-EPP tissue targets, the structural basis 
for other tissue-protective cytokines and the 
properties of IL-6 as a regenerative cytokine. 
The chapter on IL-6 is highly relevant as this 
cytokine, often regarded as a pro-inflamma-
tory cytokine, is often a protective cytokine. 
Galun and Stefan-Rose-John present their 
Tissue-Protective Cytokines is an up-to-date 
collection of articles edited by Pietro Ghezzi 
and Anthony Cerami (1). These editors are 
the leaders in the field, primarily with their 
pioneering studies on the ability of erythro-
poietin (EPO) to protect from cell death. The 
book is unique in many ways. Many chapters 
(19 Chapters) contain detailed methods and 
protocols for the experimental models, par-
ticularly in the brain and nervous system. 
This is an added benefit to the book because 
it helps the reader understand the models 
being used to evaluate the mechanism as well 
as the efficacy of tissue-protective cytokines 
that are being considered for therapies in 
various diseases. Most of the chapters review 
published studies or present new data on the 
properties and mechanism of action of EPO.
As written in the Preface by Cerami, the 
EPO story starts with well know clinical 
observation in hemodialysis patients being 
treated with EPO for low level of hemoglobin. 
The patients, weak from years of low hemo-
globin, feel better much faster and time-wise 
significantly before there is any increase in 
red blood cell mass. This suggested that EPO 
possessed another property. This observation 
encouraged Cerami, Ghezzi, and their col-
laborators to look carefully for the effect of 
EPO in animal models of inflammation. As 
pointed out in the Preface, Cerami’s studies 
on the tissue-protective properties of EPO 
led to the development of novel small mol-
ecules that do not stimulate erythropoiesis 
but rather protect against loss of cell func-
tion. The long-term collaboration of Ghezzi 
and Cerami on the inflammatory properties 
of tumor necrosis factor (TNFα) allowed for 
a new collaboration focused on the non-
erythrogenic properties of EPO. Ghezzi is a 
Review of tissue-protective cytokines
Charles A. Dinarello1,2*
1 Department of Medicine, University of Colorado Denver, Aurora, CO, USA
2 Department of Experimental Medicine, Radboud University, Nijmegen, Netherlands
*Correspondence: cdinare333@aol.com
Edited by:
Kendall A. Smith, Weill Medical College of Cornell University, USA
Keywords: inflammation, EPO, cytokine biology, erythroid progenitor cells, erythropoietic cytokine, neuroprotective, non‑erythropoietic EPO, platelets
A book review on
Tissue-Protective Cytokines: Methods and Protocols
by Pietro Ghezzi and Anthony Cerami (Editors), Humana Press, 2013, Vol. 982, 393 pages. ISBN 978-1-62703-307-7
studies on Hyper IL-6 which delivers a 
potent signal for liver regeneration. What 
remains unclear is why IL-6 blockade with 
anti-IL-6 receptor is effective in treat-
ing rheumatoid arthritis. If IL-6 signaling 
induces regeneration, the treatment of rheu-
matoid arthritis patients  with  anti-IL-6 R 
should reduce joint  integrity. One is left with 
the conundrum that the efficacy of anti-IL-6 
R in rheumatoid arthritis is due to a reduc-
tion in B-cell function more than any anti-
inflammatory property.
There are several chapters that discuss 
how EPO protects against brain and spinal 
cord injury. Related to the neuroprotective 
properties of EPO, there is an interesting 
chapter on rodent behavior as related to 
depression. This area of investigation, that 
is, cytokines that affect depression, is not 
restricted to rodent experiments. Indeed, 
Kevin Tracey has been a leader in the area 
of brain cytokines. In fact, for many years 
we know that patients with rheumatoid 
arthritis receiving an intravenous infusion 
of anti-TNFα antibodies have a near imme-
diate improvement in sense of well-being 
which is unrelated to any effect of TNFα 
blockade peripherally, and there are reports 
that anti-TNFα is an anti-depressant. Since 
EPO crosses the blood brain barrier, one 
could easily conclude from reading these 
chapters that EPO could be used as an 
anti-depressant. Indeed, small molecule 
EPO mimetic analogs, such as ARA 290, 
which is active orally, and that triggers the 
tissue-protective, anti-inflammatory effects 
of EPO, could be used to treat depression.
Related to this field is a chapter on the 
methods for studying pharmacologic treat-
ment of post-traumatic neuropathic pain. 
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ischemic-re-perfusion. There is also a list of 
clinical trials with EPO administered at vari-
ous time points following acute myocardial 
infarction. Most studies on the list result in 
a non-significant effect on the primary end-
point with one exception. An Italian study in 
patients treated with EPO within 6 h of the 
infarction showed a  statistically significant 
reduction in the infarct size as determined 
by level of enzymes and also a statistically 
significant increase in left ventricular ejec-
tion fraction at 6 months following an initial 
dose of EPO at soon after the infarct and a 
second dose at 24 and 48 h. This trial, like the 
stroke trials are essentially why the field will 
grow and mature.
This book, the first of its kind, will serve 
a vital function for those entering the field.
Also related to this area is the observation 
that EPO can be used to reduce the periph-
eral neuropathy that develops in rats with 
type 1 diabetes.
In addition to the intellectual excellence 
of this book, many chapters contain detail 
explanations with diagrams in the various 
models, particular in studies on nerves and 
the brain.
No study on the anti-inflammatory prop-
erties of a tissue-protective cytokines such as 
EPO would be complete without a study using 
the model of acute myocardial  infarction in 
mice. The chapter by Talan and Latini is 
excellent. This chapter contains a detailed 
review of EPO’s ability to reduce infarct size 
in animal models of total left anterior coro-
nary artery occlusion as well as models of 
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